Repeat prescriptions account for a substantial proportion of all prescribing in primary care. While they improve convenience, they can also mask developing safety concerns — particularly when monitoring lapses or when medications continue beyond their original indication. This tool identifies potential risk flags based on prescription duration, medication class, and any gaps in required clinical monitoring.
Use this tool during repeat prescription audits, when reviewing patients who have been on the same medications for an extended period, or when preparing for a structured medication review. It is particularly useful for pharmacy teams conducting batch prescription reviews.
This tool screens for common repeat prescription risks based on three input categories. It does not check for specific drug interactions, contraindications, or individual patient clinical records. Flagged risks should be investigated as part of standard clinical practice.
A screening assessment that identifies potential safety concerns with ongoing repeat prescriptions, such as missing monitoring, long duration without review, or high-risk drug classes.
NICE recommends that repeat prescriptions should be reviewed at least annually, with higher-risk medications reviewed more frequently — often every 3–6 months.
A monitoring gap is when required blood tests, clinical measurements, or other checks have not been completed within the recommended timeframe for a particular medication.
No. This tool focuses on prescription management risks. For interaction checking, consult your clinical system's interaction database or a dedicated interaction checker.
This tool is designed for pharmacists, prescribers, and pharmacy technicians involved in repeat prescription management and medication safety reviews.
Risk flags should be investigated and addressed as part of clinical practice. Prioritise high-risk flags and communicate findings to the relevant prescriber or clinical team.